Intra-Cellular Therapies (ITCI) PT Raised to $71 at Goldman Sachs
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Join SI Premium – FREE
Goldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $71.00 (from $64.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Incyte (INCY) PT Raised to $105 at Truist Securities
- Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink
- Plexus (PLXS) PT Raised to $330 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, The Children's Investment Fund (TCI)Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
